Apellis Pharmaceuticals

Overview

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company founded in 2009 and based in Waltham, Massachusetts. The company specializes in developing targeted therapies that inhibit the complement system, particularly the C3 protein, to treat diseases caused by immune overactivation. Apellis has made significant strides in complement science, focusing on delivering innovative therapies for rare diseases.

The company has successfully brought two first-in-class C3-targeting medicines to market. Empaveli™ (pegcetacoplan) was approved by the FDA in 2021 for paroxysmal nocturnal hemoglobinuria (PNH), and Syfovre™ (pegcetacoplan injection) received FDA approval in 2023 for geographic atrophy (GA), a major cause of vision loss. Apellis is committed to advancing its pipeline of complement-based treatments to improve patient care and address unmet medical needs. Under the leadership of its founders, Apellis emphasizes a culture of inclusivity and corporate responsibility, focusing on patient access and environmental sustainability.

Basic Information

Contact Details

• Phone: +1 617-977-5700
• Website: apellis.com
• LinkedIn: linkedin.com/company/apellis

Key Focus Areas & Initiatives

• Targeted C3 therapies
• Complement system inhibition
• Hematology
• Ophthalmology
• Nephrology
• Paroxysmal nocturnal hemoglobinuria
• Geographic atrophy
• C3 glomerulopathy
• Cold agglutinin disease
• Gene therapy
• Neurology
• Amyotrophic lateral sclerosis
• Biotechnology research
• Immune system intervention
• Regulatory compliance
• Complement cascade control
• Scientific research
• Patient outcomes
• Rare diseases
• Immune response modulation
• Biopharmaceutical development
• Innovative science
• Disease pathways
• Therapeutic development
• Targeted medicine
• Clinical trials
• Immune system diseases
• Life-changing medicines
• Medical research
• Complement-based therapy
• Healthcare solutions
• Corporate responsibility
• Patient advocacy
• Scientific integrity
• Innovative treatments
• Community engagement
• Sustainable practices
• Diversity and inclusion
• Health economics
• Environmental stewardship
• Patient support
• Scientific breakthroughs
• Retinal diseases
• Drug development
• Patient-centric approach
• Research & development

Technologies Used

• Amazon AWS
• Drupal
• Google AdWords Conversion
• Google Analytics
• Google Tag Manager
• Mailchimp Mandrill
• Microsoft Excel
• Microsoft Office
• Microsoft Office 365
• Microsoft PowerPoint
• Mobile Friendly
• OnCore CTMS
• Outlook
• Remote
• Route 53
• Salesforce
• Salesforce CRM Analytics
• Sendgrid
• Slack
• Veeva Systems
• Vimeo
• WordPress.org
• Workday
• reCAPTCHA

Affiliated Organizations & Regional Branches